整合位点分析技术的研究进展

doi:10.19586/j.2095-2341.2023.0104

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 66-71.DOI: 10.19586/j.2095-2341.2023.0104

• 生物制品研发与技术专题 • 上一篇下一篇

整合位点分析技术的研究进展

张永红(), 李岩异(), 张卫婷

华北制药金坦生物技术股份有限公司，石家庄 050035

收稿日期:2023-09-01 接受日期:2023-11-02 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 李岩异
作者简介:张永红 E-mail: yhzh9967@163.com；

Progress on Integration Site Analysis Technology

Yonghong ZHANG(), Yanyi LI(), Weiting ZHANG

North China Pharmaceutical Jintan Biotechnology Co. ，Ltd. ，Shijiazhuang 050035，China

Received:2023-09-01 Accepted:2023-11-02 Online:2024-01-25 Published:2024-02-05
Contact: Yanyi LI

摘要/Abstract

摘要：

慢病毒载体已被广泛用于将外源DNA转移到人类细胞中治疗各种遗传疾病。慢病毒载体可以整合到宿主基因组中，但整合位点通常不可预测，这可能会增加其治疗效果的不确定性。随着基因及细胞疗法的广泛应用，监管机构出台了一系列技术指导文件，以确保产品持续的安全性。整合位点分析（integration site analysis，ISA）是通过表征基因治疗载体的整合图谱来评估其生物安全性，也是转基因细胞进行克隆跟踪的关键工具。概述了用于逆转录病毒整合位点的技术演变，以及信息分析工具的优势和发展趋势，总结了减低病毒随机整合至基因组中的应对策略，以期为慢病毒载体的整合位点分析检测和细胞治疗产品新药临床试验安全性评估提供参考。

关键词: 整合位点分析, 信息分析工具, 生物安全性, 基因及细胞疗法

Abstract:

Lentiviral vectors have been widely used to transfer exogenous DNA into human cells to treat various genetic diseases. Lentiviral vectors can integrate into the host genome， but their integration sites are often unpredictable， which may increase the uncertainty of their therapeutic efficacy. With the wide application of gene and cell therapy， regulators have also issued a series of technical guidance documents to ensure the continuous safety of products. Integration site analysis （ISA） is a key tool for evaluating the biological safety of gene therapy vectors by characterizing their integration profiles， as well as for tracking transgenic cells. This review mainly described the technological evolution of integration sites for retroviruses， and the advantages and development trends of analysis methods. At the same time， strategies to reduce the random integration of viruses into the genome were also reviewed， in order to provide reference for the analysis and detection of lentiviral vector integration as a point of view and the safety evaluation of new drug clinical trials in cell therapy products.

Key words: integration site analysis, information analysis tools, biosafety, gene and cell therapy

中图分类号:

Q812

张永红, 李岩异, 张卫婷. 整合位点分析技术的研究进展[J]. 生物技术进展, 2024, 14(1): 66-71.

Yonghong ZHANG, Yanyi LI, Weiting ZHANG. Progress on Integration Site Analysis Technology[J]. Current Biotechnology, 2024, 14(1): 66-71.

参考文献 34

1	权春菊,郑忠亮.CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展[J].生物技术进展,2021,11(4):518-525.
	QUAN C J, ZHENG Z L. Application progress of CRISPR/cas and its derivative editing technology in gene therapy[J]. Curr. Biotechnol., 2021, 11(4): 518-525.
2	SHAO L, SHI R, ZHAO Y, et al.. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products[J/OL]. J. Transl. Med., 2022, 20(1): 514[2023-11-24]. .
3	SCHENKWEIN D, AFZAL S, NOUSIAINEN A, et al.. Efficient nuclease-directed integration of lentivirus vectors into the human ribosomal DNA locus[J]. Mol. Ther. J. Am. Soc. Gene Ther., 2020, 28(8): 1858-1875.
4	GABRIEL R, SCHMIDT M, VON KALLE C. Integration of retroviral vectors[J]. Curr. Opin. Immunol., 2012, 24(5): 592-597.
5	ROHDEWOHLD H, WEIHER H, REIK W, et al.. Retrovirus integration and chromatin structure: moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites[J]. J. Virol., 1987, 61(2): 336-343.
6	SALINAS J, ZERIAL M, FILIPSKI J, et al.. Nonrandom distribution of MMTV proviral sequences in the mouse genome[J]. Nucleic Acids Res., 1987, 15(7): 3009-3022.
7	MAXAM A M, GILBERT W. A method for determining DNA sequence by labeling the end of the molecule and cleaving at the base. Isolation of DNA fragments, end-labeling, cleavage, electrophoresis in polyacrylamide gel and analysis of results[J]. Mol. Biol., 1986, 20(3): 581-638.
8	SANGER F, NICKLEN S, COULSON A R. DNA sequencing with chain-terminating inhibitors[J]. Drug Des. Dev. Ther., 1977, 74(12): 5463-5467.
9	CALOS M P, JOHNSRUD L, MILLER J H. DNA sequence at the integration sites of the insertion element IS1[J]. Cell, 1978, 13(3): 411-418.
10	ROSE E A. Applications of the polymerase chain reaction to genome analysis[J]. FASEB J., 1991, 5(1): 46-54.
11	PRYCIAK P M, MÜLLER H P, VARMUS H E. Simian virus 40 minichromosomes as targets for retroviral integration in vivo [J]. Proc. Natl. Acad. Sci. USA, 1992, 89(19): 9237-9241.
12	SØRENSEN A B, DUCH M, AMTOFT H W, et al.. Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3[J]. J. Virol., 1996, 70(6): 4063-4070.
13	ROSENTHAL A, JONES D S. Genomic walking and sequencing by oligo-cassette mediated polymerase chain reaction[J]. Nucleic Acids Res., 1990, 18(10): 3095-3096.
14	CORRE G, SEYE A, FRIN S, et al.. Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells[J]. Gene Ther., 2022, 29(9): 536-543.
15	GILLET N A, MALANI N, MELAMED A, et al.. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones[J]. Blood, 2011, 117(11): 3113-3122.
16	WAGNER T A, MCLAUGHLIN S, GARG K, et al.. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection[J]. Science, 2014, 345(6196): 570-573.
17	王梦雨,王颢潜,王旭静,等.基因编辑产品检测技术研究进展[J].生物技术进展,2021,11(4):438-445.
	WANG M Y, WANG H Q, WANG X J, et al.. Research progress of gene editing products detection technology[J]. Curr. Biotechnol., 2021, 11(4): 438-445.
18	VAN HAASTEREN J, MUNIS A M, GILL D R, et al.. Genome-wide integration site detection using Cas9 enriched amplification-free long-range sequencing[J/OL]. Nucleic Acids Res., 2021, 49(3): e16[2023-11-20]. .
19	KIM H S, WANG G H, LEE H K, et al.. CReVIS-Seq: a highly accurate and multiplexable method for genome-wide mapping of lentiviral integration sites[J]. Mol. Ther. Methods Clin. Dev., 2021, 20: 792-800.
20	AFZAL S, WILKENING S, VON KALLE C, et al.. GENE-IS: time-efficient and accurate analysis of viral integration events in large-scale gene therapy data[J]. Mol. Ther. Nucleic Acids, 2017, 6: 133-139.
21	PETERS B, DIRSCHERL S, DANTZER J, et al.. Automated analysis of viral integration sites in gene therapy research using the SeqMap web resource[J]. Gene Ther., 2008, 15(18): 1294-1298.
22	AFZAL S, FRONZA R, SCHMIDT M. VSeq-toolkit: comprehensive computational analysis of viral vectors in gene therapy[J]. Mol. Ther. Meth. Clin. Dev., 2020, 17: 752-757.
23	SHEN-GUNTHER J, CAI H, WANG Y. HPV integration site mapping: a rapid method of viral integration site (VIS) analysis and visualization using automated workflows in CLC microbial genomics[J/OL]. Int. J. Mol. Sci., 2022, 23(15): 8132[2023-11-24]. .
24	JUANES J M, GALLEGO A, TÁRRAGA J, et al.. VISMapper: Ultra-fast exhaustive cartography of viral insertion sites for gene therapy[J/OL]. BMC Bioinform., 2017, 18(1): 421[2023-11-24]. .
25	HO D W H, SZE K M F, NG I O L. Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability[J]. Oncotarget, 2015, 6(25): 20959-20963.
26	SHERMAN E, NOBLES C, BERRY C C, et al.. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes[J]. Mol. Ther. Meth. Clin. Dev., 2017, 4: 39-49.
27	TANG D, LI B, XU T, et al.. VISDB: a manually curated database of viral integration sites in the human genome[J]. Nucleic Acids Res., 2020, 48(D1): 633-641.
28	高朗,于思雪,袁春森,等.黏蛋白在肿瘤免疫治疗中的研究进展[J].生物技术进展,2023,13(3):390-398.
	GAO L, YU S X, YUAN C S, et al.. Research progress of mucin in tumor immunotherapy[J]. Curr. Biotechnol., 2023, 13(3): 390-398.
29	YODER K E, RABE A J, FISHEL R, et al.. Strategies for targeting retroviral integration for safer gene therapy: advances and challenges[J/OL]. Front. Mol. Biosci., 2021, 8: 662331[2023-11-23]. .
30	高维崧,窦金萍,韦双,等.CRISPR/Cas系统的分类及研究现状[J].生物技术进展,2022,12(4):532-538.
	GAO W S, DOU J P, WEI S, et al.. Classification and research status of CRISPR/Cas systems[J]. Curr. Biotechnol., 2022, 12(4): 532-538.
31	BALKE-WANT H, KEERTHI V, CADINANOS-GARAI A, et al.. Non-viral chimeric antigen receptor (CAR) T cells going viral[J/OL]. Immuno Oncol. Technol., 2023, 18: 100375[2023-11-24]. .
32	POLETTI V, MAVILIO F. Designing lentiviral vectors for gene therapy of genetic diseases[J/OL]. Viruses, 2021, 13(8): 1526[2023-11-24]. .
33	盖思宇,陈子奇,夏涵超,等.基因编辑技术在植物启动子编辑中的研究进展[J].生物技术进展,2023,13(3):321-328.
	GAI S Y, CHEN Z Q, XIA H C, et al.. Research progress of CRISPR/Cas9 technology in plant promoter editing[J]. Curr. Biotechnol., 2023, 13(3): 321-328.
34	YEW C T, GURUMOORTHY N, NORDIN F, et al.. Integrase deficient lentiviral vector: prospects for safe clinical applications[J/OL]. PeerJ, 2022, 10: e13704[2023-11-23]. .

整合位点分析技术的研究进展

Progress on Integration Site Analysis Technology

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 1

编辑推荐

Metrics

本文评价